<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-665" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nisoldipine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sidhu</surname>
            <given-names>Gursharan</given-names>
          </name>
          <aff>Avalon University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hashmi</surname>
            <given-names>Muhammad F.</given-names>
          </name>
          <aff>National Health Service</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gursharan Sidhu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Hashmi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-665.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Nisoldipine, a dihydropyridine calcium channel blocker,&#x000a0;is a&#x000a0;drug used for the management of hypertension. This medication exerts its therapeutic effects by inhibiting calcium influx and blocking voltage-gated calcium channels in systemic smooth muscle cells. By reducing calcium levels, nisoldipine dilates coronary and systemic arteries.&#x000a0;According&#x000a0;to the American College of Cardiology/American Heart Association guidelines, nisoldipine is recommended as a first-line therapy for hypertension. It can be&#x000a0;used&#x000a0;as a standalone treatment or with other antihypertensive agents, such as angiotensin-converting enzyme inhibitors, diuretics, or beta-blockers. Additionally, this drug exhibits potential off-label applications for addressing ischemic heart conditions, including stable angina and Prinzmetal angina. This activity explores nisoldipine's indications, contraindications, adverse effects, and essential factors such as dosing, pharmacodynamics, pharmacokinetics, monitoring, and pertinent interactions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients who may benefit from nisoldipine therapy based on their medical history, blood pressure readings, and cardiovascular risk factors.</p></list-item><list-item><p>Differentiate nisoldipine from other calcium-channel blockers by understanding its specific pharmacokinetic and pharmacodynamic properties.</p></list-item><list-item><p>Implement appropriate dosing regimens and treatment plans for patients receiving nisoldipine, considering individualized factors such as age, comorbidities, and concurrent medications.</p></list-item><list-item><p>Develop collaboration&#x000a0;with other healthcare professionals to ensure coordinated care and comprehensive management of patients receiving nisoldipine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=665&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=665">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-665.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Nisoldipine is an FDA-approved 1,4-dihydropyridine calcium-channel blocker for the management of hypertension. The drug may be used alone or with other antihypertensive agents (eg, angiotensin-converting enzyme inhibitors, diuretics, or beta-blockers). The American College of Cardiology/American Heart Association guidelines for hypertension recommend calcium channel blockers, including nisoldipine, as one of the first-line therapies for hypertension.<xref ref-type="bibr" rid="article-665.r1">[1]</xref><xref ref-type="bibr" rid="article-665.r2">[2]</xref>&#x000a0;The medication is also safe and effective for use in older&#x000a0;patients.<xref ref-type="bibr" rid="article-665.r3">[3]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Nisoldipine may be used off-label for treating ischemic heart conditions such as stable angina and Prinzmetal angina.<xref ref-type="bibr" rid="article-665.r4">[4]</xref></p>
      </sec>
      <sec id="article-665.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Nisoldipine falls under the class of dihydropyridine calcium channel blockers. The drug acts on the systemic smooth muscle cells by inhibiting the influx of calcium and blocking the voltage-gated calcium channels located in the cells; the reduction in the calcium results in the dilation of coronary and systemic arteries. Nisoldipine exhibits antihypertensive and anti-anginal activity due to its ability to reduce systemic blood pressure and the myocardial oxygen demand (thereby increasing myocardial oxygen delivery to cells).<xref ref-type="bibr" rid="article-665.r5">[5]</xref>&#x000a0;This action ultimately results in vasodilation and decreases peripheral vascular resistance. Nisoldipine is comparatively more potent vasodilator than nifedipine.<xref ref-type="bibr" rid="article-665.r6">[6]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption: </bold>The bioavailability of nisoldipine is low (5%) due to extensive first-pass (pre-systemic) metabolism.<xref ref-type="bibr" rid="article-665.r7">[7]</xref>&#x000a0;Administration with high-fat meals significantly increases the&#x000a0;peak plasma concentration and reduces nisoldipine's exposure/AUC (area under the curve).</p>
        <p><bold>Distribution: </bold>Plasma protein binding of nisoldipine is high. Nisoldipine can penetrate the blood-brain barrier.<xref ref-type="bibr" rid="article-665.r8">[8]</xref></p>
        <p><bold>Metabolism:&#x000a0;</bold>Nisoldipine is metabolized in the liver CYP3A4 pathway and excreted through the renal pathway.<xref ref-type="bibr" rid="article-665.r9">[9]</xref></p>
        <p><bold>Elimination: </bold>Nisoldipine and its metabolites are excreted predominantly by the kidney. The elimination half-life is&#x000a0;13.7 &#x000b1; 4.3 hours.<xref ref-type="bibr" rid="article-665.r10">[10]</xref></p>
      </sec>
      <sec id="article-665.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Nisoldipine is available&#x000a0;in an oral formulation, as an extended-release tablet (20 mg, 30 mg, and 40 mg) or as an extended-release hydrogel (8.5 mg, 17 mg, and 34 mg). The patient should take the medication on an empty stomach or an hour after meals. The drug must be swallowed whole with water and not crushed or divided.<xref ref-type="bibr" rid="article-665.r11">[11]</xref> The dosing adjustment recommendations are on weekly intervals based on patient response. Avoid grapefruit juice and high-fat meals&#x000a0;with medication administration because they affect drug bioavailability.<xref ref-type="bibr" rid="article-665.r12">[12]</xref></p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>
<bold>Hypertension</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Extended-release hydrogel is started at 17 mg by mouth daily, and the maximum daily dose is 34 mg by mouth daily.<xref ref-type="bibr" rid="article-665.r1">[1]</xref>&#x000a0;The dosage&#x000a0;is increased by 8.5 mg weekly or at longer intervals to achieve optimum blood pressure. The maintenance dose for nisoldipine ranges between 17 to 34 mg daily. In comparison, the original extended-release formulation is started at 20 mg/d and goes up to a maximum dosage of 40 mg daily. The dose is increased every&#x000a0;2 to&#x000a0;4 weeks for optimum blood pressure control. These formulations can be combined with ACE inhibitors, ARBs, beta-blockers, or thiazide diuretics if monotherapy is insufficient to attain the blood pressure goal.</p>
          </list-item>
        </list>
        <p>
<bold>Ischemic Heart Conditions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For ischemic heart disease, nisoldipine&#x000a0;can be initiated at&#x000a0;8.5 mg once daily; the dose can be gradually titrated to 34 mg&#x000a0;once daily.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>The concentration of nisoldipine&#x000a0;is approximately&#x000a0;4 to 5-fold&#x000a0;higher in&#x000a0;patients&#x000a0;with cirrhosis.<xref ref-type="bibr" rid="article-665.r13">[13]</xref> Starting with the lowest dose is recommended. The recommended dose is&#x000a0;8.5 to 10 mg orally daily (do not exceed 30 mg daily).</p>
        <p><bold>Renal impairment:&#x000a0;</bold>Because nisoldipine's pharmacokinetics are not significantly different in patients with various degrees of renal impairment, dose adjustments are&#x000a0;not required in patients with mild to moderate renal impairment.</p>
        <p><bold>Pregnancy considerations:</bold> No clinical data regarding nisoldipine in pregnancy exists. According to ACOG guidelines, chronic hypertension may result in substantial maternal, fetal, and neonatal morbidity and mortality. Patients may be treated with calcium channel blockers; however, nifedipine&#x000a0;is preferred.<xref ref-type="bibr" rid="article-665.r14">[14]</xref></p>
        <p><bold>Breastfeeding considerations</bold>: There is inadequate clinical data regarding the use of nisoldipine during lactation. Breastfeeding women should avoid this drug due to the risk of excretion into breast milk.<xref ref-type="bibr" rid="article-665.r15">[15]</xref></p>
        <p><bold>Pediatric patients:</bold> The safety and efficacy of nisoldipine in the pediatric patient population have not been established.</p>
        <p><bold>Older patients:</bold>&#x000a0;Caution is necessary for&#x000a0;older patients due to higher drug plasma concentrations; recommendations are to start at a lower dose for safety. The recommended starting dose for hypertension is 8.5 mg once daily.</p>
        <p>The equivalency of the nisoldipine dose is as follows:</p>
        <table-wrap id="article-665.table0" position="float" orientation="portrait">
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr style="height: 26px;">
                <td style="width: 284.75px; height: 26px;" rowspan="1" colspan="1">Original Extended-Release Formulation</td>
                <td style="width: 52.25px; height: 26px;" rowspan="1" colspan="1">10 mg</td>
                <td style="width: 51px; height: 26px;" rowspan="1" colspan="1">20 mg</td>
                <td style="width: 50px; height: 26px;" rowspan="1" colspan="1">30 mg</td>
                <td style="width: 61px; height: 26px;" rowspan="1" colspan="1">40 mg</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 284.75px; height: 26px;" rowspan="1" colspan="1">Extended-Release Hydrogel (newer) Formulation</td>
                <td style="width: 52.25px; height: 26px;" rowspan="1" colspan="1">8.5 mg</td>
                <td style="width: 51px; height: 26px;" rowspan="1" colspan="1">17 mg</td>
                <td style="width: 50px; height: 26px;" rowspan="1" colspan="1">25.5 mg</td>
                <td style="width: 61px; height: 26px;" rowspan="1" colspan="1">34 mg</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-665.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Though nisoldipine is well-tolerated among patients, the drug does have some side effects mainly associated with its vasodilating property. Common adverse effects associated with nisoldipine include flushing, vasodilation (4%), hypotension, syncope, peripheral edema (7% to 29%,dose-related), headache (22%), dizziness (3% to 10%), and nausea (2%).<xref ref-type="bibr" rid="article-665.r16">[16]</xref></p>
        <p>Additionally, adverse reactions such as chest pain (2%), palpitations (3%), dermatitis&#x000a0;(2%), pharyngitis (5%), and sinusitis&#x000a0;(3%)&#x000a0;are reported in&#x000a0;patients taking nisoldipine.&#x000a0;Occasional adverse effects (less than 1% of the population) include&#x000a0;anemia, anxiety, alopecia, dysphagia, and gingival hyperplasia.<xref ref-type="bibr" rid="article-665.r17">[17]</xref></p>
        <p>In less than 1% of the population taking nisoldipine, the following adverse reactions are reported in postmarketing surveillance.</p>
        <p>Increased blood urea nitrogen, increased creatine phosphokinase, abnormal hepatic function, increased serum creatinine, anorexia,&#x000a0;hepatomegaly, abnormal dreams,&#x000a0;amnesia,&#x000a0;ataxia,&#x000a0;cerebral ischemia,&#x000a0; cerebrovascular accident,&#x000a0;depression,&#x000a0;drowsiness,&#x000a0; insomnia, abnormal T waves on ECG,&#x000a0;ejection murmur (systolic),&#x000a0;first-degree atrioventricular block, atrial fibrillation, supraventricular tachycardia, amblyopia,&#x000a0;blepharitis,&#x000a0;diaphoresis, glaucoma,&#x000a0;keratoconjunctivitis, exfoliative dermatitis, facial edema,&#x000a0;dermal ulcer,&#x000a0;hypersensitivity reaction, maculopapular rash,&#x000a0;increased appetite, oral mucosa ulcer,&#x000a0;hematuria, colitis, diarrhea,&#x000a0;dysgeusia, dyspepsia, dysuria, epistaxis, gastritis, gastrointestinal bleeding, glossitis,&#x000a0;leukopenia, malaise, melena,&#x000a0;fever, flu-like symptoms, arthralgia, arthritis,&#x000a0;gout, bruise, herpes simplex infection, herpes zoster, cellulitis,&#x000a0;dyspnea, decreased libido, and gynecomastia is reported by manufacturer's product label.</p>
        <p>In patients&#x000a0;receiving&#x000a0;peritoneal dialysis, there is a risk of nisoldipine-associated chyloperitoneum.<xref ref-type="bibr" rid="article-665.r18">[18]</xref></p>
        <p><bold>Withdrawal Effects:</bold> Studies have shown that the abrupt withdrawal of nisoldipine may result in chest palpitations, chest pain, or increased severity of angina or hypertension. Thus, the medication must be slowly tapered over time.<xref ref-type="bibr" rid="article-665.r18">[18]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nisoldipine is a substrate of the CYP3A4 enzyme. Avoid concurrent use of nisoldipine with cytochrome P450 inducers such as phenytoin.<xref ref-type="bibr" rid="article-665.r19">[19]</xref>&#x000a0;Rifamycins&#x000a0;are inducers of cytochrome P450; avoid concurrent use with nisoldipine.<xref ref-type="bibr" rid="article-665.r20">[20]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Avoid the concurrent use of nisoldipine with cytochrome P450 inhibitors such as itraconazole, as it can increase the serum concentration of nisoldipine and increase the risk of toxicity.<xref ref-type="bibr" rid="article-665.r21">[21]</xref><xref ref-type="bibr" rid="article-665.r22">[22]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Concurrent administration of calcium channel blockers with dantrolene increases the risk of hyperkalemia.<xref ref-type="bibr" rid="article-665.r23">[23]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nisoldipine has the potential to interact with garlic and turmeric. Nisoldipine acts upon UGT (UDP-glucuronosyltransferase).&#x000a0;Garlic and turmeric inhibit UGT,&#x000a0;which can increase the serum&#x000a0;concentration of&#x000a0;nisoldipine. Avoid concurrent administration.<xref ref-type="bibr" rid="article-665.r24">[24]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-665.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Nisoldipine is contraindicated in individuals with hypersensitivity to the drug or other dihydropyridine calcium channel blockers. Nisoldipine-induced small bowel angioedema has been reported.<xref ref-type="bibr" rid="article-665.r25">[25]</xref></p>
        <p>Due to the lack of well-controlled studies, pregnant/breastfeeding women should avoid drug use to prevent teratogenicity.&#x000a0;Nisoldipine is also contraindicated with grapefruit products and high-fat meals due&#x000a0;to its effect on absorption.<xref ref-type="bibr" rid="article-665.r26">[26]</xref><xref ref-type="bibr" rid="article-665.r27">[27]</xref>&#x000a0;Patients&#x000a0;diagnosed with GERD or a hiatal hernia should exercise caution when using nisoldipine due to its action on the esophageal sphincter.<xref ref-type="bibr" rid="article-665.r28">[28]</xref>&#x000a0;</p>
        <p>
<bold>Warnings/Precautions</bold>
</p>
        <p><bold>Hypotension/syncope:</bold>&#x000a0;Hypotension with or without syncope is rarely reported, and target blood pressure should be attained at a rate appropriate for the patient's clinical condition. Clinicians should closely monitor patients during initial dosing and at dosage titrations.</p>
        <p><bold>Peripheral edema:</bold> The most common adverse reaction of nisoldipine is peripheral edema, which occurs within&#x000a0;2 to&#x000a0;3 weeks of therapy initiation. A prescribing cascade occurs when the edema&#x000a0;is diagnosed&#x000a0;as a new medical condition, and a diuretic is&#x000a0;administered to&#x000a0;manage the edema.<xref ref-type="bibr" rid="article-665.r29">[29]</xref></p>
        <p><bold>Angina/myocardial infarction:</bold> Extreme caution is necessary for patients with aortic stenosis,&#x000a0;myocardial infarction, or hypotension due to the risk of reflex tachycardia resulting in the possible exacerbation of angina or worsening of myocardial infarction (MI),&#x000a0;especially in the absence of concomitant beta-blockade. Though rare, patients with coronary artery disease may have increased frequency or severity of angina&#x000a0;after starting nisoldipine. Safety measures are advised in patients with&#x000a0;heart failure or left ventricular dysfunction and severe bradycardia due to the drug's hypotensive effect.</p>
        <p><bold>Heart Failure:</bold>&#x000a0;According to ACC/AHA heart failure guidelines, calcium channel blockers should be avoided in patients with heart failure due to lack of benefit and worsening of outcomes.<xref ref-type="bibr" rid="article-665.r30">[30]</xref></p>
        <p><bold>Hepatic Impairment</bold>: Use nisoldipine with caution in patients with severe hepatic impairment.<xref ref-type="bibr" rid="article-665.r9">[9]</xref></p>
      </sec>
      <sec id="article-665.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Individuals taking nisoldipine should&#x000a0;be monitored for symptoms and any adverse effects of the medication. The medication should be stored in a cool place, away from heat and moisture.<xref ref-type="bibr" rid="article-665.r3">[3]</xref>&#x000a0;</p>
        <p>The patient's blood pressure should be carefully observed during each clinic visit and at home. Monitoring cardiac function (eg, heart rate) for any abnormalities at each physician visit is essential, with dose adjustments made accordingly. It is also crucial to taper the dose slowly and adjust it at weekly intervals.&#x000a0;Liver function test (LFT) monitoring is required in individuals with hepatic impairment. No dose adjustments are necessary for renal impairment.<xref ref-type="bibr" rid="article-665.r16">[16]</xref>&#x000a0;According to ACC/AHA guidelines, ASCVD risk should be estimated for the primary prevention of cardiovascular diseases for patients with hypertension.<xref ref-type="bibr" rid="article-665.r31">[31]</xref></p>
      </sec>
      <sec id="article-665.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Toxicity due to nisoldipine is diagnosed based on clinical status and history. As described above, hypotension with reflex tachycardia can&#x000a0;occur when patients take excessive doses of dihydropyridine calcium channel blockers such as&#x000a0;nisoldipine. In some severe cases of&#x000a0;nisoldipine toxicity, the clinician will note hypotension with bradycardia. Secondary findings of confusion, heart failure, and abnormal ECG changes such as PR prolongation can indicate toxicity. Additionally, hyperglycemia in patients without diabetes can suggest calcium channel blockers poisoning.<xref ref-type="bibr" rid="article-665.r32">[32]</xref></p>
        <p>If toxicity is suspected, resuscitation is a priority. IV fluids and atropine for bradycardia are necessary alongside frequent reassessments by clinical staff. If a patient presents with severe symptoms, maintaining the airway, IV isotonic crystalloid, calcium salts, glucagon, insulin, and vasopressor therapy are all viable options. Activated charcoal should be administered to all patients suspected of&#x000a0;nisoldipine overdose.<bold>&#x000a0;</bold>Due to high plasma protein binding, dialysis is usually ineffective in nisoldipine overdose. Extracorporeal life support&#x000a0;is associated with improved survival&#x000a0;in patients with severe CCB poisoning related to cardiac arrest.<xref ref-type="bibr" rid="article-665.r28">[28]</xref></p>
      </sec>
      <sec id="article-665.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>In the United States, hypertension&#x000a0;is one of the most common reasons for atherosclerotic cardiovascular disease (ASCVD)-related deaths.<xref ref-type="bibr" rid="article-665.r33">[33]</xref>&#x000a0;Calcium channel blockers are widely used in&#x000a0;the management of hypertension.&#x000a0;An interprofessional healthcare team is the optimal means to successfully manage patients treated with dihydropyridine calcium channel blockers such as nisoldipine to address indicated pathologies.</p>
        <p>Providers must be knowledgeable regarding the symptoms of toxicity. A team of physicians, advanced practice practitioners, nurses, laboratory technicians, pharmacists, and other healthcare professionals is necessary to optimize care to improve clinical outcomes in overdose cases. Pharmacists should&#x000a0;provide accurate information regarding&#x000a0;administering glucagon, insulin, and vasopressor therapy. A toxicologist consult should also take place when indicated. Cardiologists, intensivists, and the emergency team may be involved in managing a patient further, as many of these cases require further interventional management during the hospital course, including maintenance of an airway. By coordinating care, a patient on nisoldipine experiencing toxicity or adverse symptoms can be successfully managed.</p>
        <p>Interprofessional team dynamics will also serve to prevent adverse reactions to nisoldipine. The prescriber can consult a pharmacist to verify dosing and check the medication record for potential drug interactions. Nurses can perform the necessary monitoring at follow-up visits and help determine patient compliance and treatment effectiveness, informing the prescriber and making recommendations as appropriate. The pharmacist and nursing should promptly alert the prescriber to any concerns so medication adjustments (dosing or agent selection) can improve patient outcomes.</p>
      </sec>
      <sec id="article-665.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=665&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=665">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/665/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=665">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-665.s11">
        <title>References</title>
        <ref id="article-665.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>e13</fpage>
            <page-range>e13-e115</page-range>
            <pub-id pub-id-type="pmid">29133356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Ma&#x000f1;as</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sareli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Heinig</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Nisoldipine CC: clinical experience in hypertension.</article-title>
            <source>Cardiology</source>
            <year>1997</year>
            <volume>88 Suppl 1</volume>
            <fpage>56</fpage>
            <page-range>56-62; discussion 63-5</page-range>
            <pub-id pub-id-type="pmid">9118169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenz</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Wurdeman</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Hilleman</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from amlodipine to nisoldipine.</article-title>
            <source>Pharmacotherapy</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>21</volume>
            <issue>8</issue>
            <fpage>898</fpage>
            <page-range>898-903</page-range>
            <pub-id pub-id-type="pmid">11718496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thadani</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Zellner</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Glasser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bittar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Montoro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Chaitman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schulman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>DiBianco</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris.</article-title>
            <source>Circulation</source>
            <year>1991</year>
            <month>Dec</month>
            <volume>84</volume>
            <issue>6</issue>
            <fpage>2398</fpage>
            <page-range>2398-408</page-range>
            <pub-id pub-id-type="pmid">1959195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Antianginal and anti-ischemic efficacy of nisoldipine in stable angina pectoris: a randomized, double-blind, placebo-controlled trial.</article-title>
            <source>Zhonghua Yi Xue Za Zhi (Taipei)</source>
            <year>1996</year>
            <month>Nov</month>
            <volume>58</volume>
            <issue>5</issue>
            <fpage>323</fpage>
            <page-range>323-8</page-range>
            <pub-id pub-id-type="pmid">9037847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cacabelos</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Naidoo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Corzo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cacabelos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Carril</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.</article-title>
            <source>Int J Mol Sci</source>
            <year>2021</year>
            <month>Dec</month>
            <day>10</day>
            <volume>22</volume>
            <issue>24</issue>
            <pub-id pub-id-type="pmid">34948113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El Maghraby</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Elsergany</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Fast disintegrating tablets of nisoldipine for intra-oral administration.</article-title>
            <source>Pharm Dev Technol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>641</fpage>
            <page-range>641-50</page-range>
            <pub-id pub-id-type="pmid">23841582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colbourne</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders.</article-title>
            <source>Mol Psychiatry</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>27</volume>
            <issue>9</issue>
            <fpage>3904</fpage>
            <page-range>3904-3912</page-range>
            <pub-id pub-id-type="pmid">35618884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <chapter-title>Nisoldipine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>1</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">31643685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dudhipala</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Veerabrahma</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design.</article-title>
            <source>Drug Dev Ind Pharm</source>
            <year>2015</year>
            <volume>41</volume>
            <issue>12</issue>
            <fpage>1968</fpage>
            <page-range>1968-77</page-range>
            <pub-id pub-id-type="pmid">25830370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dudhipala</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Janga</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Gorre</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.</article-title>
            <source>Artif Cells Nanomed Biotechnol</source>
            <year>2018</year>
            <volume>46</volume>
            <issue>sup2</issue>
            <fpage>616</fpage>
            <page-range>616-625</page-range>
            <pub-id pub-id-type="pmid">29688077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rameis</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Principles of the pharmacokinetics and pharmacodynamics of calcium antagonists].</article-title>
            <source>Wien Med Wochenschr</source>
            <year>1993</year>
            <volume>143</volume>
            <issue>19-20</issue>
            <fpage>490</fpage>
            <page-range>490-500</page-range>
            <pub-id pub-id-type="pmid">8135031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krol</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sundaresan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lettieri</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lasseter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of Nisoldipine Coat--Core Formulation in Subjects with Liver Cirrhosis.</article-title>
            <source>Am J Ther</source>
            <year>1995</year>
            <month>Jan</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-19</page-range>
            <pub-id pub-id-type="pmid">11850642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins&#x02014;Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>133</volume>
            <issue>1</issue>
            <fpage>e26</fpage>
            <page-range>e26-e50</page-range>
            <pub-id pub-id-type="pmid">30575676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <chapter-title>Nisoldipine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>10</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">30000110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Saunders</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Noveck</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ferdinand</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension.</article-title>
            <source>Am J Hypertens</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9 Pt 1</issue>
            <fpage>739</fpage>
            <page-range>739-45</page-range>
            <pub-id pub-id-type="pmid">12944032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tajani</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Nesbitt</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Gingival hyperplasia in a patient with hypertension.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>10</volume>
            <issue>11</issue>
            <fpage>863</fpage>
            <page-range>863-5</page-range>
            <pub-id pub-id-type="pmid">19128276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2019</year>
            <month>Apr</month>
            <day>13</day>
            <volume>16</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">31013922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perucca</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Clinically relevant drug interactions with antiepileptic drugs.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>246</fpage>
            <page-range>246-55</page-range>
            <pub-id pub-id-type="pmid">16487217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nahid</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dorman</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Alipanah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barry</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cattamanchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chaisson</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Chaisson</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Grzemska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Higashi</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Hopewell</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Keshavjee</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Lienhardt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Merrifield</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Narita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peloquin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Raftery</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saukkonen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schaaf</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Sotgiu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Starke</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Migliori</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Vernon</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>Oct</month>
            <day>01</day>
            <volume>63</volume>
            <issue>7</issue>
            <fpage>e147</fpage>
            <page-range>e147-e195</page-range>
            <pub-id pub-id-type="pmid">27516382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ikemura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yamaori</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kamijo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Murayama</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yamazaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ohmori</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine.</article-title>
            <source>Chem Biol Interact</source>
            <year>2019</year>
            <month>Jun</month>
            <day>01</day>
            <volume>306</volume>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">30965050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guengerich</surname>
                <given-names>FP</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of Cytochrome P450 Enzymes by Drugs-Molecular Basis and Practical Applications.</article-title>
            <source>Biomol Ther (Seoul)</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-18</page-range>
            <pub-id pub-id-type="pmid">34475272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schneiderbanger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Johannsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roewer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Management of malignant hyperthermia: diagnosis and treatment.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2014</year>
            <volume>10</volume>
            <fpage>355</fpage>
            <page-range>355-62</page-range>
            <pub-id pub-id-type="pmid">24868161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prieto-Garcia</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Alkhabbaz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Mazzari</surname>
                <given-names>ALDA</given-names>
              </name>
            </person-group>
            <article-title>Potential Pharmacokinetic Interactions of Common Cardiovascular Drugs and Selected European and Latin American Herbal Medicines: A Scoping Review.</article-title>
            <source>Plants (Basel)</source>
            <year>2023</year>
            <month>Jan</month>
            <day>31</day>
            <volume>12</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">36771707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turcu</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kulaga</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Skluth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gruss</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Calcium channel blocker-associated small bowel angioedema.</article-title>
            <source>J Clin Gastroenterol</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>338</fpage>
            <page-range>338-41</page-range>
            <pub-id pub-id-type="pmid">19077729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bailey</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Dresser</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Interactions between grapefruit juice and cardiovascular drugs.</article-title>
            <source>Am J Cardiovasc Drugs</source>
            <year>2004</year>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>281</fpage>
            <page-range>281-97</page-range>
            <pub-id pub-id-type="pmid">15449971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stouras</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Papaioannou</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Tsioufis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eliopoulos</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Sanoudou</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The Challenge and Importance of Integrating Drug-Nutrient-Genome Interactions in Personalized Cardiovascular Healthcare.</article-title>
            <source>J Pers Med</source>
            <year>2022</year>
            <month>Mar</month>
            <day>22</day>
            <volume>12</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">35455629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>St-Onge</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dub&#x000e9;</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Gosselin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guimont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Godwin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Archambault</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Chauny</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Frenette</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Darveau</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Le Sage</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Poitras</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Provencher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Juurlink</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Blais</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Treatment for calcium channel blocker poisoning: a systematic review.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>52</volume>
            <issue>9</issue>
            <fpage>926</fpage>
            <page-range>926-44</page-range>
            <pub-id pub-id-type="pmid">25283255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savage</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Visentin</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Bronskill</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gruneir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giannakeas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Luke</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Read</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Stall</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rochon</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of a Common Prescribing Cascade of Calcium Channel Blockers and Diuretics in Older Adults With Hypertension.</article-title>
            <source>JAMA Intern Med</source>
            <year>2020</year>
            <month>May</month>
            <day>01</day>
            <volume>180</volume>
            <issue>5</issue>
            <fpage>643</fpage>
            <page-range>643-651</page-range>
            <pub-id pub-id-type="pmid">32091538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>WRITING COMMITTEE MEMBERS</collab>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Jessup</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Geraci</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Horwich</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Masoudi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Riegel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sam</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Wilkoff</surname>
                <given-names>BL</given-names>
              </name>
              <collab>American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</collab>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Oct</month>
            <day>15</day>
            <volume>128</volume>
            <issue>16</issue>
            <fpage>e240</fpage>
            <page-range>e240-327</page-range>
            <pub-id pub-id-type="pmid">23741058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnett</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Buroker</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Goldberger</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Himmelfarb</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Khera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McEvoy</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Michos</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Miedema</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Yeboah</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ziaeian</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular&#x000a0;Disease: A Report of the American College of Cardiology/American Heart Association Task&#x000a0;Force&#x000a0;on&#x000a0;Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2019</year>
            <month>Sep</month>
            <day>10</day>
            <volume>74</volume>
            <issue>10</issue>
            <fpage>e177</fpage>
            <page-range>e177-e232</page-range>
            <pub-id pub-id-type="pmid">30894318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wachowiak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Strach</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lopatka</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>[Toxicological analysis of selected 1,4-dihydropyridine calcium channel blockers in the diagnosis of intoxications].</article-title>
            <source>Arch Med Sadowej Kryminol</source>
            <year>2005</year>
            <season>Jan-Mar</season>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-54</page-range>
            <pub-id pub-id-type="pmid">15984121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-665.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnett</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Buroker</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Goldberger</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Himmelfarb</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Khera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McEvoy</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Michos</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Miedema</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Yeboah</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ziaeian</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task&#x000a0;Force&#x000a0;on&#x000a0;Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2019</year>
            <month>Sep</month>
            <day>10</day>
            <volume>74</volume>
            <issue>10</issue>
            <fpage>1376</fpage>
            <page-range>1376-1414</page-range>
            <pub-id pub-id-type="pmid">30894319</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
